Minority Women Successfully Recruited for Dietary Fat Study

Publication
Article
OncologyONCOLOGY Vol 12 No 3
Volume 12
Issue 3

Postmenopausal minority women can be successfully recruited for a program to reduce dietary fat and can achieve significant changes in their eating habits, stated Carolyn K. Clifford, phd, at the 1997 Biennial Symposium on Minorities, the Medically Underserved, and Cancer in Washington, DC.

Postmenopausal minority women can be successfully recruited for a program to reduce dietary fat and can achieve significant changes in their eating habits, stated Carolyn K. Clifford, phd, at the 1997 Biennial Symposium on Minorities, the Medically Underserved, and Cancer in Washington, DC.

The Women’s Health Trial focus on minority group members, which involved a 3-year multicenter clinical trial, finished about a year ago, she reported. Although not presenting data or results from the trial, Clifford, chief of the National Cancer Institute Diet and Cancer Branch noted that 2,250 women participated, most of them from households earning between $15,000 and $50,000 per year, and one-fourth from households earning below $15,000. At the outset of the trial, they were consuming an average of 38% of their calories from fat.

A number of strategies resulted in recruitment of minority women, Clifford said, including mailings, mass media presentation, encouragement from friends, and community outreach. Recruitment yield proved to be lower among poorer women than among those of middle income or above.

Current NCI Trials

A variety of dietary studies supported by the NCI currently aim to test the feasibility of lowering fat in women’s diets to 15% to 20% of daily calories, as well as the relationship of that dietary change to a number of specific cancers. The dietary intervention trials focus on introducing more fruits, vegetables, whole grains, and fiber into the daily diet and also on reducing fat. The objective is to see whether such changes in adults can lower the incidence of cancer. Dietary intake measurements used include food frequency questionnaires, food records, and 24-hour recall.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content